Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

213
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
213
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

488
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
488
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

1.4K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.4K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

1.9K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

394
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
394
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

393
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
393

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing unmet needs for patients with erectile dysfunction: a narrative review of topical therapies.

Sexual medicine·2025
Same author

Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis.

The lancet. Healthy longevity·2023
Same author

Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis.

The lancet. Healthy longevity·2022
Same author

The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline.

The Journal of urology·2022
Same author

Shock Wave Therapy for Peyronie's Disease-Learning From the Past and Looking Into the Future.

The journal of sexual medicine·2022
Same author

Erectile dysfunction guideline: A missed opportunity?

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2021

Related Experiment Video

Updated: Jan 2, 2026

Intracavernous Pressure Recording in a Cavernous Nerve Injury Rat Model
05:48

Intracavernous Pressure Recording in a Cavernous Nerve Injury Rat Model

Published on: September 20, 2021

1.9K

Intracavernous pharmacotherapy for erectile dysfunction.

Anthony J Bella1, Gerald B Brock

  • 1The Department of Surgery, Division of Urology, St. Joseph's Health Center, The University of Western Ontario, London, Ontario, Canada. susans2@sjhc.london.on.ca

Endocrine
|May 18, 2004
PubMed
Summary

Intracavernous injections for erectile dysfunction (ED) remain a viable second-line treatment, with ongoing research into new agents promising improved efficacy and tolerability. Future therapies aim to enhance this established ED treatment method.

More Related Videos

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.0K
Cavernous Nerve Stimulation and Recording of Intracavernous Pressure in a Rat
07:43

Cavernous Nerve Stimulation and Recording of Intracavernous Pressure in a Rat

Published on: April 23, 2018

13.3K

Related Experiment Videos

Last Updated: Jan 2, 2026

Intracavernous Pressure Recording in a Cavernous Nerve Injury Rat Model
05:48

Intracavernous Pressure Recording in a Cavernous Nerve Injury Rat Model

Published on: September 20, 2021

1.9K
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.0K
Cavernous Nerve Stimulation and Recording of Intracavernous Pressure in a Rat
07:43

Cavernous Nerve Stimulation and Recording of Intracavernous Pressure in a Rat

Published on: April 23, 2018

13.3K

Area of Science:

  • Urology
  • Pharmacology
  • Reproductive Medicine

Background:

  • Phosphodiesterase type-5 inhibitors are now standard oral therapy for erectile dysfunction (ED).
  • Intracavernous injection (ICI) of vasoactive agents is currently a second-line treatment for ED.
  • Despite oral therapies, ICI remains crucial for specific patient populations and offers a safe, effective option.

Purpose of the Study:

  • To review the functional anatomy and physiology of human penile erection.
  • To discuss current clinical vasoactive agents used for ED.
  • To explore emerging and future therapeutic agents for erectile dysfunction.

Main Methods:

  • Review of functional anatomy and physiology of penile erection.
  • Analysis of current clinical vasoactive agents (prostaglandin E-1, papaverine, phentolamine).
  • Discussion of emerging therapies (guanylate cyclase activators, potassium channel openers, nitric oxide donors, VIP, CGRP, alpha-1 antagonists, gene therapy).

Main Results:

  • Established vasoactive agents provide effective treatment for erectile dysfunction.
  • Numerous novel agents and therapeutic strategies are under investigation.
  • Research aims to improve efficacy, tolerability, and onset of action for ICI therapies.

Conclusions:

  • Intracavernous injection therapy for ED is a time-tested, safe, and effective treatment.
  • Ongoing research and development are expanding the range of agents and improving outcomes.
  • Future advancements in ICI promise to make it a more appealing option for diverse ED etiologies and comorbidities.